Bio

Chris is a Partner of Bridgepoint with responsibility for Bridgepoint Europe. He also sits on the Firm’s Executive Committee and is a member of its Investment Advisory Committee. He joined the Firm in 1997. He currently sits on the board of Vermaat and historical transactions include Element, PharmaZell, ACT, Vitamin Well, LGC, ERM, Pret A Manger, CEG, and the delisting of Exova. Chris has a BSc from Exeter University and is ACA qualified from his time spent working at PwC prior to joining Bridgepoint.